Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy

This study has been terminated.
(no change in primary endpoint at week 48)
Sponsor:
Collaborators:
The University of New South Wales
Abbott
Bristol-Myers Squibb
Gilead Sciences
GlaxoSmithKline
Merck Sharp & Dohme Corp.
Hoffmann-La Roche
AIDS Council of New South Wales
Information provided by:
Kirby Institute
ClinicalTrials.gov Identifier:
NCT00126308
First received: August 1, 2005
Last updated: March 31, 2009
Last verified: March 2009

August 1, 2005
March 31, 2009
November 2005
May 2007   (final data collection date for primary outcome measure)
The primary endpoint at 24 weeks will be change from baseline in facial soft tissue volume as measured by spiral computed tomography (CT). [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
The primary endpoint at 24 weeks will be change from baseline in facial soft tissue volume as measured by spiral computed tomography (CT).
Complete list of historical versions of study NCT00126308 on ClinicalTrials.gov Archive Site
  • Change from baseline at week 96 in facial soft tissue volume as measured by spiral CT scan [ Time Frame: 96 weeks ] [ Designated as safety issue: No ]
  • Change from baseline at weeks 24 and 96 in physician and patient assessment of facial lipoatrophy severity [ Time Frame: 24 and 96 weeks ] [ Designated as safety issue: No ]
  • Change from baseline at weeks 24 and 96 in peripheral fat as assessed by dual-energy X-ray absorptiometry (DEXA) [ Time Frame: 24 and 96 weeks ] [ Designated as safety issue: No ]
  • Change from baseline at weeks 24 and 96 in quality of life [ Time Frame: 24 and 96 weeks ] [ Designated as safety issue: No ]
  • Change from baseline at weeks 24 and 96 in antiretroviral therapy (ART) adherence and plasma HIV-RNA [ Time Frame: 24 and 96 weeks ] [ Designated as safety issue: No ]
  • All serious, grade 3 or 4 clinical adverse events and any adverse event leading to change/s in ART or discontinuation of PLA [ Time Frame: 24 and 96 weeks ] [ Designated as safety issue: Yes ]
  • All serious, grade 3 or 4 clinical adverse events (AEs) and any event leading to change/s in ART reported to week 96 [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]
  • All AEs attributable to study treatment reported to week 96 [ Time Frame: week 96 ] [ Designated as safety issue: Yes ]
  • - Change from baseline at week 96 in facial soft tissue volume as measured by spiral CT scan
  • - Change from baseline at weeks 24 and 96 in physician and patient assessment of facial lipoatrophy severity
  • - Change from baseline at weeks 24 and 96 in peripheral fat as assessed by dual-energy X-ray absorptiometry (DEXA)
  • - Change from baseline at weeks 24 and 96 in quality of life
  • - Change from baseline at weeks 24 and 96 in antiretroviral therapy adherence and plasma HIV-RNA
  • - All serious, grade 3 or 4 clinical adverse events and any adverse event leading to change/s in ART or discontinuation of PLA
  • - All serious, grade 3 or 4 clinical adverse events (AEs) and any event leading to change/s in ART reported to week 96
  • - All AEs attributable to study treatment reported to week 96
Not Provided
Not Provided
 
Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy
A Multi-Centre, Open-Label, Randomised Study to Assess the Efficacy, Durability and Safety of Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy (FLASH)

This is a multi-centre, open-label, 96 week study to evaluate the safety, tolerability and extent and duration of improvement in HIV-1 infected subjects with antiretroviral induced facial lipoatrophy, randomised in a 1:1 ratio to receive immediate or deferred deep subcutaneous injections of poly-L-lactic acid (PLA). Subjects will receive 4 treatments of PLA approximately every 2nd week, either at trial entry or following a delay period of 24 weeks.

HIV lipodystrophy can be distressing and result in suboptimal antiretroviral (ART) adherence. Physical changes may stigmatise subjects while the negative psychological and social impact has become a major concern. To date, as there is no proven therapy for lipoatrophy, cosmetic interventions for facial lipoatrophy are being studied. Poly-L-lactic acid (PLA) has been shown to be both safe and effective when administered by injection to facial areas.

Study aims are:

  1. to evaluate the extent and duration of improvement in HIV facial lipoatrophy of PLA injections;
  2. to evaluate the impact of PLA injections on quality of life and ART adherence in subjects with HIV facial lipoatrophy;
  3. to evaluate the safety and tolerability of polylactic acid.

100 HIV-infected ART-experienced subjects with facial lipoatrophy will be randomised in a 1:1 ratio at study entry to receive either immediate or deferred treatment (delayed 24 weeks) treatment with PLA. Randomisation will be stratified by age, severity of facial lipoatrophy, current ART (PI or non-PI containing and thymidine- or non-thymidine-containing) and surgeon.

The study has clinical end points monitoring CD4 cell counts, viral loads and adverse events. The study also has psychosocial end points monitoring quality of life.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • HIV-Associated Lipodystrophy
  • HIV Infections
  • Device: poly-L-lactic acid
    immediate injections poly-L-lactic acid (4 bilateral treatments - 8 vials)
    Other Name: Sculptra
  • Device: poly-L-lactic acid
    delayed (24 weeks) poly-L-lactic acid injections (4 bilateral treatment - 8 vials)
    Other Name: Sculptra
  • Experimental: Immediate
    poly-L-lactic acid injections
    Intervention: Device: poly-L-lactic acid
  • Active Comparator: Delayed
    poly-L-lactic acid injections
    Intervention: Device: poly-L-lactic acid
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
100
May 2007
May 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Aged 18 years or more with laboratory evidence of HIV-1 infection
  • Received combination antiretroviral therapy (minimum of 2 agents)
  • Antiretroviral regimen should be stable for at least 12 weeks prior to entry with no changes planned during the first 48 weeks. For subjects not on antiretroviral therapy at entry there should be no intent to commence therapy in first 24 weeks.
  • Moderate or severe facial lipoatrophy and lipodystrophy at one or more other sites
  • Provide written, informed consent.

Exclusion Criteria:

  • Active AIDS-defining illness including active HIV wasting
  • Active herpes labialis or any acute or currently present chronic skin disease (infection/inflammation) on/near area to be treated
  • Currently on anticoagulants or any coagulopathy that would preclude safe deep subcutaneous injections
  • Women: pregnant, breastfeeding or have positive pregnancy test or not willing to use adequate contraception if of child-bearing potential
  • Concomitant therapy with anabolic steroids (except testosterone replacement), corticosteroids at greater than replacement doses, growth hormone or any currently available or experimental agent to improve appetite or weight
  • Testosterone replacement for less than 6 months or at greater than replacement doses
  • Subjects who have discontinued any prohibited concomitant agent/s must cease this therapy at least 30 days prior to screening.
  • Prior use of any facial dermal filling/tissue expansion agent/s
  • Any condition which may interfere with ability to comply with study requirements.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Australia
 
NCT00126308
V1-0 4-05, ACTR012605000132640
No
The National Centre in HIV Epidemiology and Clinical Research
Kirby Institute
  • The University of New South Wales
  • Abbott
  • Bristol-Myers Squibb
  • Gilead Sciences
  • GlaxoSmithKline
  • Merck Sharp & Dohme Corp.
  • Hoffmann-La Roche
  • AIDS Council of New South Wales
Principal Investigator: Andrew Carr, A/Prof Immunology and Infectious Disease Unit, St. Vincent's Hospital, Sydney
Kirby Institute
March 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP